Background: In recent years experience has been accumulated in percutaneous radiofrequency ablation (RFA) of lung malignancies in nonsurgical patients. Objectives: In this study, we retrospectively evaluated a simultaneous diagnostic and therapeutic approach including CT-guided biopsy followed immediately by RFA of solitary malignant pulmonary lesions. Methods: CT-guided transthoracic core needle biopsy of solitary pulmonary lesions suspicious for malignancy was performed and histology was proven based on immediate frozen sections. RFA probes were placed into the pulmonary tumors under CT guidance and the ablation was performed subsequently. The procedure-related morbidity was analyzed. Follow-up included a CT scan and pulmonary function parameters. Results: A total of 33 CT-guided biopsies and subsequent RFA within a single procedure were performed. Morbidity of CT-guided biopsy included pulmonary hemorrhage (24%) and a mild pneumothorax (12%) without need for further interventions. The RFA procedure was not aggravated by the previous biopsy. The rate of pneumothorax requiring chest tube following RFA was 21%. Local tumor control was achieved in 77% with a median follow-up of 12 months. The morbidity of the CT-guided biopsy had no statistical impact on the local recurrence rate. Conclusions: The simultaneous diagnostic and therapeutic approach including CT-guided biopsy followed immediately by RFA of solitary malignant pulmonary lesions is a safe procedure. The potential of this combined approach is to avoid unnecessary therapies and to perform adequate therapies based on histology. Taking the local control rate into account, this approach should only be performed in those patients who are unable to undergo or who refuse surgery.

Keywords:
Biopsy, Chest CT, Chest interventions, Interventional radiology, Lung cancer treatment, Pulmonary nodules
1.
Mery CM, Pappas AN, Bueno R, Mentzer SJ, Lukanich JM, Sugarbaker DJ, Jaklitsch MT: Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. Chest 2004;125:2175–2181.
2.
Grgic A, Yuksel Y, Groschel A, Schafers HJ, Sybrecht GW, Kirsch CM, Hellwig D: Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging 2010;37:1087–1094.
3.
Sakamoto M, Murakawa T, Kitano K, Murayama T, Tsuchiya T, Nakajima J: Resection of solitary pulmonary lesion is beneficial to patients with a history of malignancy. Ann Thorac Surg 2010;90:1766–1771.
4.
Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R: Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011;6:1601–1612.
5.
Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, Massion PP, Walker R, Grogan EL: Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg 2011;92:428–433.
6.
Ambrosini V, Rubello D: Is there an ideal diagnostic algorithm in solitary pulmonary nodules? Respiration 2006;73:587–589.
7.
Naalsund A, Maublant J: The solitary pulmonary nodule – is it malignant or benign? Diagnostic performance of Tc-depreotide SPECT. Respiration 2006;73:634–641.
8.
Eberhardt R, Ernst A, Herth FJ: Ultrasound-guided transbronchial biopsy of solitary pulmonary nodules less than 20 mm. Eur Respir J 2009;34:1284–1287.
9.
Eberhardt R, Kahn N, Gompelmann D, Schumann M, Heussel CP, Herth FJ: Lungpoint – a new approach to peripheral lesions. J Thorac Oncol 2010;5:1559–1563.
10.
Schwarz Y, Mehta AC, Ernst A, Herth F, Engel A, Besser D, Becker HD: Electromagnetic navigation during flexible bronchoscopy. Respiration 2003;70:516–522.
11.
Lu CH, Hsiao CH, Chang YC, Lee JM, Shih JY, Wu LA, Yu CJ, Liu HM, Shih TT, Yang PC: Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol 2012;7:143–150.
12.
Eberhardt R, Morgan RK, Ernst A, Beyer T, Herth FJ: Comparison of suction catheter versus forceps biopsy for sampling of solitary pulmonary nodules guided by electromagnetic navigational bronchoscopy. Respiration 2010;79:54–60.
13.
Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, et al: Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the rapture study). Lancet Oncol 2008;9:621–628.
14.
Hiraki T, Gobara H, Mimura H, Matsui Y, Toyooka S, Kanazawa S: Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2011;142:24–30.
15.
Dadrich M, Schneider T, Puderbach M, Kauczor HU, Heussel CP: Moving pleural mass. Med Klin Intensivmed Notfmed 2012;107:213–215.
16.
Cheung YC, Chang JW, Hsieh JJ, Lin G, Tsai YH: Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer 2010;67:166–169.
17.
Yao X, Gomes MM, Tsao MS, Allen CJ, Geddie W, Sekhon H: Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. Curr Oncol 2012;19:e16–e27.
18.
Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP, Ost DE: Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:108S–130S.
19.
Laurent F, Latrabe V, Vergier B, Michel P: Percutaneous CT-guided biopsy of the lung: comparison between aspiration and automated cutting needles using a coaxial technique. Cardiovasc Intervent Radiol 2000;23:266–272.
20.
Anderson JM, Murchison J, Patel D: CT-guided lung biopsy: factors influencing diagnostic yield and complication rate. Clin Radiol 2003;58:791–797.
21.
Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Hamamoto S, Toyoshima M, Nakamura K, Miki Y: Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution. Cardiovasc Intervent Radiol 2010;33:787–793.
22.
Yasui K, Kanazawa S, Sano Y, Fujiwara T, Kagawa S, Mimura H, Dendo S, Mukai T, Fujiwara H, Iguchi T, et al: Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience. Radiology 2004;231:850–857.
23.
Fernando HC, De Hoyos A, Landreneau RJ, Gilbert S, Gooding WE, Buenaventura PO, Christie NA, Belani C, Luketich JD: Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005;129:639–644.
24.
Lanuti M, Sharma A, Digumarthy SR, Wright CD, Donahue DM, Wain JC, Mathisen DJ, Shepard JA: Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:160–166.
25.
Kishi K, Nakamura H, Kobayashi K, Hashimoto T, Hatao H, Oh-ishi S, Matsuoka T: Percutaneous CT-guided radiofrequency ablation of pulmonary malignant tumors: preliminary report. Intern Med 2006;45:65–72.
26.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2006;303:1070–1076.
27.
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, et al: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94–S100.
28.
Dupuy DE: Image-guided thermal ablation of lung malignancies. Radiology 2011;260:633–655.
29.
Pennathur A, Luketich JD, Abbas G, Chen M, Fernando HC, Gooding WE, Schuchert MJ, Gilbert S, Christie NA, Landreneau RJ: Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 2007;134:857–864.
30.
Zhu JC, Yan TD, Glenn D, Morris DL: Radiofrequency ablation of lung tumors: feasibility and safety. Ann Thorac Surg 2009;87:1023–1028.
31.
Yamakado K, Hase S, Matsuoka T, Tanigawa N, Nakatsuka A, Takaki H, Takao M, Inoue Y, Kanazawa S, Sawada S, et al: Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol 2007;18:393–398.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.